EWA
SRPT icon

Evolution Wealth Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Evolution Wealth Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-190
Closed -$18K – 557
2021
Q3 		$18K Sell
190
-232
-55% -$17.9K ﹤0.01% 327
2021
Q2 		$33K Buy
422
+40
+10% +$3.03K 0.01% 245
2021
Q1 		$28K Buy
382
+168
+79% +$15.5K 0.01% 254
2020
Q4 		$36K Sell
214
-22
-9% -$3.26K 0.01% 204
2020
Q3 		$33K Buy
236
+21
+10% +$3.19K 0.01% 221
2020
Q2 		$34K Sell
215
-32
-13% -$4.36K 0.01% 164
2020
Q1 		$24K Buy
247
+48
+24% +$5.49K 0.01% 143
2019
Q4 		$26K Buy
199
+183
+1,144% +$18.5K 0.01% 203
2019
Q3 		$1K Sell
16
-148
-90% -$17.5K ﹤0.01% 467
2019
Q2 		$25K Buy
+164
New +$19.9K 0.01% 116

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Evolution Wealth Advisors's SRPT Position: Q4 2021 in Review

Evolution Wealth Advisors sold out of Sarepta Therapeutics (SRPT) in Q4 2021, closing a stake of 190 shares — an estimated $18K sold.

Evolution Wealth Advisors first reported a position in SRPT in Q2 2019 and held it in 10 quarters. The position peaked at $36K in Q4 2020. 343 funds tracked by Wall St. Rank hold SRPT as of Q4 2021.

  • Evolution Wealth Advisors reported no remaining Sarepta Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Evolution Wealth Advisors sold 190 Sarepta Therapeutics shares in Q4 2021, an estimated $18K.
  • Evolution Wealth Advisors first reported a position in Sarepta Therapeutics in Q2 2019 and held it in 10 quarters.
  • Evolution Wealth Advisors's Sarepta Therapeutics position peaked at $36K in Q4 2020.
  • 343 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2021.

Based on Evolution Wealth Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.